General Updates

Date: 15th July, 2026 To, To, BSE Limited, National Stock exchange of India Limited, Listing Department, P.J. Towers, Dalal Exchange Plaza, C-1, Block G, Street, Mumbai – 400 001 Bandra Kurla Complex, Bandra (E) Scrip Code: 532694 Mumbai – 400 051 Symbol: ASMS Dear Sir/Madam, Subject: Revised Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in reference of earlier intimations dated April 08, 2026 With reference to our disclosure dated 08th April, 2026 submitted under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") with respect to the Company's investment in Huwel Lifesciences Private Limited ("Huwel"). The Company wishes to inform the Stock Exchanges that certain particulars relating to the amount of investment and percentage of shareholding disclosed in the intimation dated April 08, 2026 require revision. Accordingly, it is hereby clarified that the Company has made a further investment in Huwel Lifesciences Private Limited aggregating to INR 7,50,00,400/- (Indian Rupees Seven Crore Fifty Lakhs Four Hundred Only) instead of INR 4,00,00,000 (Indian Rupees Four Crore Only) . Pursuant to the said investment, the Company has acquired 2.06% of the paid-up equity share capital of Huwel. The remaining terms and conditions of the investment, including the mode of consideration and the purpose of investment, remain unchanged. The revised disclosures pursuant to Regulation 30 of the Listing Regulations read with Part A of Schedule III thereof are enclosed herewith as Annexure – A. Except for the above revisions, all other disclosures made in the earlier intimations shall remain unchanged. This is for your information and Records. Thanking You, Yours Faithfully, For Avio Smart Market Stack limited (Formerly Known as Bartronics India Limited) Diksha Omer Company Secretary Annexure – A Particulars Details Name of the target entity M/s Huwel Lifesciences Private Limited (“Huwel”) Whether the acquisition would fall The acquisition does not fall within the ambit of within related party transactions related party transactions. The promoter/promoter and whether the group/group companies have no interest in the promoter/promoter group has any target entity. interest in the entity being acquired Industry to which the entity being Lifescience and Health acquired belongs Objects and effects of acquisition To derive operational and financial synergies. brief details of any governmental or Not Applicable regulatory approvals required for the acquisition indicative time period for Acquisition has been completed completion of the acquisition Whether the acquisition is at arm’s Yes, the acquisition is to be at arm’s length basis. length Details of consideration INR 7,50,00,400/- (Indian Rupees Seven Crore Fifty Lakhs Four Hundred Only). Mode of consideration Cash Percentage of shareholding/control 2.06% of the paid-up equity share capital of Huwel. acquired Cost of acquisition or the price at The Company will get 9665 equity shares at a price which shares are acquired of INR 7760/- per share, including a premium of INR 7750/- per share brief background about the entity Date of incorporation: Huwel Lifesciences Private acquired in terms of products/line Limited, (CIN: U33111TG2015PTC097596) is a of business acquired, date of Private company incorporated on 10/02/2015. incorporation, history of last 3 years turnover, country in which the Brief background: The Target Entity is engaged in acquired entity has presence and the business of development, manufacturing, and any other significant information supply of molecular diagnostic kits, medical devices, and in-vitro diagnostic solutions. And serves hospitals, laboratories, and research institutions by providing products for disease detection and healthcare testing. Turnover: 2022-23 - 12.11 Cr. 2023-24 - 4.94 Cr. 2024-25 - 15.74 Cr. Country: Patancheru, Telangana, India